Pharma R&D
Pharma R&D
Pharma R&D
Pharma R&D
Innovation Milestones
First US & China patents granted in August 2020 (Methods for determining the cause of somatic mutagenesis).
Expanded IFP profiling methods in CPAS in additional cancers, analyzing 10,000+ patients and achieving high accuracy, sensitivity and specificity.
Completed 3 lung cancer validation studies, achieving a predictive accuracy of ~91% using whole exome data in determining non-responders to immunotherapy treatment.
Clinical validation studies of Lung Cancer Treatment Response in progress for completion Q2 2025
Created world's only Scientific Reference Database linking deaminase science to molecular and clinical outcomes
2020
2024
First to identify novel Cancer Progression-Associated Signatures (CPAS) across a range of cancers.
First to use deaminase-associated mutations for predicting patient response to immuno-oncology therapies.
Healthy Population Clinical Trial (Monash Clinical Trial Precinct).
First to show that inherited human SNPs are likely caused by mutagenic deaminase activity.
First to use blood DNA to develop an Innate Fitness Score (IFP) for stratifying patients with diseases.
Proof of Concept completed predicting IO responders using >14 datasets across 5 therapies and cancers.
2016
2019
First to show that strand-biased mutation patterns seen in immune genes are the same as in many cancers.
First to show that AID/APOBEC and ADAR deaminase- associated mutations occur in protein reading– frame context.
Initiated basic research to identify deaminase signatures.
First patent application (Federal Government Innovation Support Grant).
First platform built to automate genomic analysis.
First to identify novel Cancer-Progression Associated Signatures (CPAS) in ovarian cancer.